AV Favipiravir
| PHA antivirals by mechanism |
drug: favipiravir, avigan(r)
32401463 2006. Favipiravir
32346491 ä. Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study
32246834 2020. Favipiravir: Pharmacokinetics and Concerns About Clinical Trials for 2019-nCoV Infection
32350860 2020. Dose Rationale for Favipiravir Use in Patients Infected With SARS-CoV-2
32360327 ä. Potential repurposing of Favipiravir in COVID-19 outbreak based on current evidence
32475019 2020. Pharmacokinetics of Favipiravir in Critically Ill Patients with COVID-19.
32417899 2020. Favipiravir, an antiviral for COVID-19?
32585765 2020. A Case of Successful Treatment of Severe COVID-19 Pneumonia with Favipiravir and Tocilizumab in Post-kidney Transplant Recipient.
32536670 2020. Uric Acid Elevation by Favipiravir, an Antiviral Drug.
32405421 2020. A review of the safety of favipiravir - a potential treatment in the COVID-19 pandemic?
32353191 2020. Response to "Dose Rationale for Favipiravir Use in Patients Infected With SARS-CoV-2".
32620147 2020. Nafamostat mesylate treatment in combination with favipiravir for patients critically ill with Covid-19: a case series.
32646499 2020. Effect of favipiravir and an anti-inflammatory strategy for COVID-19.
32711596 2020. Interactions Between Remdesivir, Ribavirin, Favipiravir, Galidesivir, Hydroxychloroquine and Chloroquine with Fragment Molecular of the COVID-19 Main Protease with Inhibitor N3 Complex (PDB ID:6LU7) Using Molecular Docking.
32727996 2020. Acute Gouty Arthritis During Favipiravir Treatment for Coronavirus Disease 2019.
32787901 2020. Adverse events associated with nafamostat mesylate and favipiravir treatment in COVID-19 patients.
32829044 2020. Case studies of SARS-CoV-2 treated with favipiravir among patients in critical or severe condition.
32834770 2020. Favipiravir tautomerism: a theoretical insight.
32836314 2020. Favipiravir - a Modern Antiviral Drug: Synthesis and Modifications.
32844821 2020. Systematic Review on Repurposing Use of Favipiravir Against SARS-CoV-2.
32868989 2020. Combination treatment of short-course systemic corticosteroid and favipiravir in a successfully treated case of critically ill COVID-19 pneumonia with COPD.
32886358 2020. Tolerability of Favipiravir therapy in critically-ill patients with COVID-19: a report of 4 cases.
32888000 2020. Comment on: Favipiravir, an antiviral for COVID-19?
32893160 2020. Outcome of early-stage combination treatment with favipiravir and methylprednisolone for severe COVID-19 pneumonia: A report of 11 cases.
32895599 2020. Favipiravir: A new and emerging antiviral option in COVID-19.
32943628 2020. Rapid incorporation of Favipiravir by the fast and permissive viral RNA polymerase complex results in SARS-CoV-2 lethal mutagenesis.
32958718 2020. A prospective, randomized, open-label trial of early versus late favipiravir in hospitalized patients with COVID-19.
32965359 2020. The effects of favipiravir on hematological parameters of covid-19 patients.
32967849 2020. Favipiravir and the Need for Early Ambulatory Treatment of SARS-CoV2 Infection (COVID-19).
32972430 2020. Favipiravir versus other antiviral or standard of care for COVID-19 treatment: a rapid systematic review and meta-analysis.
32977854 2020. Oral favipiravir for patients with delayed SARS-CoV-2 viral RNA clearance: a case series.
32992014 2020. Favipiravir-induced fever in coronavirus disease 2019: A report of two cases.
33031623 2020. Tackling COVID-19 Using Remdesivir and Favipiravir as Therapeutic Options.
33037151 2020. Favipiravir at high doses has potent antiviral activity in SARS-CoV-2-infected hamsters, whereas hydroxychloroquine lacks activity.
33042544 2020. Severe coronavirus disease 2019 (COVID-19) pneumonia patients treated successfully with a combination of lopinavir/ritonavir plus favipiravir: Case series.
33075124 2020. Favipiravir as an antiviral agent in COVID-19: same script, different cast?
33092045 2020. Detailed Molecular Interactions of Favipiravir with SARS-CoV-2, SARS-CoV, MERS-CoV, and Influenza Virus Polymerases In Silico.
33108587 2020. Favipiravir use for SARS CoV-2 infection.
33115675 2020. Clinical Outcomes and Plasma Concentrations of Baloxavir Marboxil and Favipiravir in COVID-19 Patients: An Exploratory Randomized, Controlled Trial.
33120121 2020. DFT calculations towards the geometry optimization, electronic structure, infrared spectroscopy and UV-vis analyses of Favipiravir adsorption on the first-row transition metals doped fullerenes; a new strategy for COVID-19 therapy.
33128482 2020. Observational study of the effects of Favipiravir vs Lopinavir/Ritonavir on clinical outcomes in critically Ill patients with COVID-19.
33130203 2020. Role of favipiravir in the treatment of COVID-19.
33176367 2020. Favipiravir and COVID-19: A Simplified Summary.
33176880 2020. Pharmacophore modelling of vanillin derivatives, favipiravir, chloroquine, hydroxychloroquine, monolaurin and tetrodotoxin as M(Pro) inhibitors of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2).
33181328 2020. Randomized Controlled Open Label Trial on the Use of Favipiravir Combined with Inhaled Interferon beta-1b in Hospitalized Patients with Moderate to Severe COVID-19 Pneumonia.
33181454 2020. The effect of favipiravir on QTc interval in patients hospitalized with coronavirus disease 2019.
33191372 2020. A Favipiravir-induced Fever in a Patient with COVID-19.
33212256 2020. Efficacy and Safety of Favipiravir, an Oral RNA-Dependent RNA Polymerase Inhibitor, in Mild-to-Moderate COVID-19: A Randomized, Comparative, Open-Label, Multicenter, Phase 3 Clinical Trial.
33237663 2020. Treatment of SARS-cov-2 pneumonia with favipiravir: Early results from the Ege University cohort, Turkey.
33251975 2020. Combination of QSAR, molecular docking, molecular dynamic simulation and MM-PBSA: analogues of lopinavir and favipiravir as potential drug candidates against COVID-19.
33268271 2020. A case of COVID-19 pneumonia successfully treated with favipiravir (Avigan) in which serum SARS-CoV-2 RNA detected by LAMP method was clinically useful.
33283773 2020. Systematic review and meta-analysis of effectiveness and safety of favipiravir in the management of novel coronavirus (COVID-19) patients.
33288636 2020. Favipiravir and the Need for Early Ambulatory Treatment of COVID-19.
33301818 2020. Clinical efficacy and safety of favipiravir in the treatment of COVID-19 patients.
C7331506 2020. A review of the safety of favipiravir ? a potential treatment in the COVID-19 pandemic?
